Heron Therapeutics Inc. (HRTX) Stock Price Down 2.3%
Heron Therapeutics Inc. (NASDAQ:HRTX) fell 2.3% during trading on Wednesday . The stock traded as low as $19.16 and last traded at $19.41, with a volume of 211,921 shares trading hands. The stock had previously closed at $19.86.
Several research firms have recently commented on HRTX. Leerink Swann reaffirmed an “outperform” rating and set a $33.00 price target on shares of Heron Therapeutics in a research report on Thursday, August 18th. Brean Capital reaffirmed a “buy” rating and set a $55.00 price target on shares of Heron Therapeutics in a research report on Saturday, August 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $38.00 price target on shares of Heron Therapeutics in a research report on Tuesday, August 9th. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 3rd. Finally, JMP Securities reaffirmed a “buy” rating on shares of Heron Therapeutics in a research report on Friday, September 9th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $47.70.
The firm has a 50-day moving average of $19.58 and a 200-day moving average of $18.95.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/heron-therapeutics-inc-hrtx-stock-price-down-2-3.html
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. On average, equities research analysts predict that Heron Therapeutics Inc. will post ($4.43) EPS for the current year.
In other news, insider Robert Rosen sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 10th. The stock was sold at an average price of $23.30, for a total value of $2,330,000.00. Following the completion of the sale, the insider now directly owns 102,640 shares in the company, valued at $2,391,512. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.31% of the stock is owned by insiders.
Several hedge funds have recently bought and sold shares of HRTX. BlackRock Group LTD raised its stake in shares of Heron Therapeutics by 174.2% in the first quarter. BlackRock Group LTD now owns 9,919 shares of the biotechnology company’s stock worth $188,000 after buying an additional 6,301 shares in the last quarter. Parametric Portfolio Associates LLC purchased a new stake in shares of Heron Therapeutics during the second quarter worth about $213,000. BlackRock Advisors LLC raised its stake in shares of Heron Therapeutics by 13.3% in the second quarter. BlackRock Advisors LLC now owns 15,104 shares of the biotechnology company’s stock worth $273,000 after buying an additional 1,769 shares in the last quarter. State Board of Administration of Florida Retirement System raised its stake in shares of Heron Therapeutics by 8.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 16,739 shares of the biotechnology company’s stock worth $302,000 after buying an additional 1,283 shares in the last quarter. Finally, American International Group Inc. raised its stake in shares of Heron Therapeutics by 8.1% in the second quarter. American International Group Inc. now owns 18,293 shares of the biotechnology company’s stock worth $330,000 after buying an additional 1,369 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.